Medullary Thyroid Carcinoma Clinical Trial
Official title:
Spanish Observational Study for MOLecular Characterization of THYroid Carcinoma MOLTHY Project
This project is a retrospective observational study based on the molecular characterization of a Spanish population of patients with refractory radio-iodine differentiated thyroid cancer (DTC) and medullary thyroid carcinoma (MTC) with advanced and / or metastatic disease undergoing systemic treatment, or under clinical observation. Three diagnostic techniques will be performed on formalin-fixed paraffin embedded (FFPE) tumor samples from the study population: immunohistochemistry (IHC), fluorescence by in situ hybridization (FISH) as well as Next-Generation Sequencing (NGS) techniques by means of DNA and RNA analysis (Ion Platform Torrent - Oncomine Focus Assay, 52 gene detection). The results of each patient will be compared in order to correlate the results of each method.
Immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) techniques will be carried out to identify NTRK and RET alterations. NTRK alterations will be identified using IHC techniques (NTRK over-expression), and FISH techniques (break-apart method). RET alterations will also be identified using the FISH technique (break-apart method). At the same time, DNA and RNA will be extracted for sequencing techniques using the Oncomine Focus Assay platform, including 52 genes (35 Hotspot genes, 19 Copy number variants and 23 Gene fusions, including NTRK and RET). ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT03636945 -
Evaluation of 18F-FDOPA PET-CT in the Preoperative Initial Assessment of Medullary Thyroid Carcinoma
|
N/A | |
Withdrawn |
NCT01736878 -
Efficacy and Safety Study of Sorafenib to Treat Advanced Medullary Thyroid Carcinoma
|
Phase 2 | |
Completed |
NCT06067594 -
Calcitonin in Needle Wash Using Electrochemiluminescence Method For Diagnosis Of Medullary Thyroid Carcinoma.
|
||
Completed |
NCT01424878 -
Study of Molecular Pathways in Medullary Thyroid Carcinoma and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients
|
||
Completed |
NCT02586350 -
Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031)
|
Phase 2/Phase 3 | |
Completed |
NCT00514046 -
Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT04787328 -
A Study of HA121-28 Tablets in Patients With Medullary Thyroid Carcinoma (MTC)
|
Phase 2 | |
Completed |
NCT01730638 -
ImmunoTEP for Patients With Medullary Thyroid Carcinoma.
|
Phase 1/Phase 2 | |
Enrolling by invitation |
NCT01511393 -
An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC)
|
||
Terminated |
NCT00923247 -
A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)
|
Phase 1/Phase 2 | |
Completed |
NCT00880503 -
Collection of Tissue Samples for Study of Multidrug Resistance
|
||
Not yet recruiting |
NCT06121271 -
Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications
|
Phase 2 | |
Completed |
NCT03246659 -
Radiolabelled CCK-2/Gastrin Receptor Analogue for Personalized Theranostic Strategy in Advanced MTC
|
Phase 1 | |
Recruiting |
NCT05534594 -
Evaluation of the 18F-PSMA Positron Emission Tomography (PET)/CT in Patients With Medullary Thyroid Cancer
|
N/A | |
Not yet recruiting |
NCT01373736 -
123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors
|
Phase 3 |